Cargando…

Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage

Edaravone dexborneol is a novel neuroprotective drug that comprises edaravone and (+)-borneol in a 4:1 ratio. Phase II and III studies have demonstrated that Chinese patients treated with edaravone dexborneol within 48 h of AIS onset have better functional outcomes than those treated with edaravone...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Qian, Cai, Yichen, Zhu, Xiaoyu, Wang, Jing, Gao, Feng, Yang, Mingfeng, Mao, Leilei, Zhang, Zongyong, Sun, Baoliang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068884/
https://www.ncbi.nlm.nih.gov/pubmed/35529450
http://dx.doi.org/10.3389/fphar.2022.848529
_version_ 1784700312961941504
author Chen, Qian
Cai, Yichen
Zhu, Xiaoyu
Wang, Jing
Gao, Feng
Yang, Mingfeng
Mao, Leilei
Zhang, Zongyong
Sun, Baoliang
author_facet Chen, Qian
Cai, Yichen
Zhu, Xiaoyu
Wang, Jing
Gao, Feng
Yang, Mingfeng
Mao, Leilei
Zhang, Zongyong
Sun, Baoliang
author_sort Chen, Qian
collection PubMed
description Edaravone dexborneol is a novel neuroprotective drug that comprises edaravone and (+)-borneol in a 4:1 ratio. Phase II and III studies have demonstrated that Chinese patients treated with edaravone dexborneol within 48 h of AIS onset have better functional outcomes than those treated with edaravone alone. However, the effect of edaravone dexborneol on subarachnoid hemorrhage (SAH) has not yet been elucidated. This study aimed to investigate the therapeutic effects of edaravone dexborneol on SAH-induced brain injury and long-term behavioral deficits and to explore the possible mechanisms. The experimental rat SAH model was induced by an intraluminal puncture of the left middle cerebral artery (MCA). Edaravone dexborneol or edaravone at a clinical dose was infused into the tail vein for 3 days post-SAH surgery. Behavioral outcomes were assessed by a modified Garcia scoring system and rotarod, foot-fault, and corner tests. Immunofluorescence, Western blot, and ELISA methods were used to evaluate neuronal damage and oxidative stress. Our results showed that a post-SAH therapeutic regimen with edaravone dexborneol helped improve neurological function up to 21 days after SAH surgery and demonstrated a greater beneficial effect than edaravone alone, accompanied by an obvious inhibition of neuronal apoptosis in the CA1 hippocampus and basal cortex regions. Mechanistically, edaravone dexborneol not only suppressed the lipid peroxidation product malondialdehyde (MDA) but also improved the total antioxidant capability (TAC) 3 days after SAH. Notably, edaravone dexborneol treatment significantly inhibited the expression of another lipid peroxidation product, 4-hydroxynonenal (4-HNE), in the CA1 hippocampus and basal cortex, which are vital participants in the process of neuronal oxidative damage and death after SAH because of their acute cytotoxicity. Together, our results demonstrate that edaravone dexborneol confers neuroprotection and stabilizes long-term behavioral ability after SAH injury, possibly by suppressing 4-HNE-associated oxidative stress. These results may help develop new clinical strategies for SAH treatment.
format Online
Article
Text
id pubmed-9068884
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90688842022-05-05 Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage Chen, Qian Cai, Yichen Zhu, Xiaoyu Wang, Jing Gao, Feng Yang, Mingfeng Mao, Leilei Zhang, Zongyong Sun, Baoliang Front Pharmacol Pharmacology Edaravone dexborneol is a novel neuroprotective drug that comprises edaravone and (+)-borneol in a 4:1 ratio. Phase II and III studies have demonstrated that Chinese patients treated with edaravone dexborneol within 48 h of AIS onset have better functional outcomes than those treated with edaravone alone. However, the effect of edaravone dexborneol on subarachnoid hemorrhage (SAH) has not yet been elucidated. This study aimed to investigate the therapeutic effects of edaravone dexborneol on SAH-induced brain injury and long-term behavioral deficits and to explore the possible mechanisms. The experimental rat SAH model was induced by an intraluminal puncture of the left middle cerebral artery (MCA). Edaravone dexborneol or edaravone at a clinical dose was infused into the tail vein for 3 days post-SAH surgery. Behavioral outcomes were assessed by a modified Garcia scoring system and rotarod, foot-fault, and corner tests. Immunofluorescence, Western blot, and ELISA methods were used to evaluate neuronal damage and oxidative stress. Our results showed that a post-SAH therapeutic regimen with edaravone dexborneol helped improve neurological function up to 21 days after SAH surgery and demonstrated a greater beneficial effect than edaravone alone, accompanied by an obvious inhibition of neuronal apoptosis in the CA1 hippocampus and basal cortex regions. Mechanistically, edaravone dexborneol not only suppressed the lipid peroxidation product malondialdehyde (MDA) but also improved the total antioxidant capability (TAC) 3 days after SAH. Notably, edaravone dexborneol treatment significantly inhibited the expression of another lipid peroxidation product, 4-hydroxynonenal (4-HNE), in the CA1 hippocampus and basal cortex, which are vital participants in the process of neuronal oxidative damage and death after SAH because of their acute cytotoxicity. Together, our results demonstrate that edaravone dexborneol confers neuroprotection and stabilizes long-term behavioral ability after SAH injury, possibly by suppressing 4-HNE-associated oxidative stress. These results may help develop new clinical strategies for SAH treatment. Frontiers Media S.A. 2022-04-21 /pmc/articles/PMC9068884/ /pubmed/35529450 http://dx.doi.org/10.3389/fphar.2022.848529 Text en Copyright © 2022 Chen, Cai, Zhu, Wang, Gao, Yang, Mao, Zhang and Sun. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Chen, Qian
Cai, Yichen
Zhu, Xiaoyu
Wang, Jing
Gao, Feng
Yang, Mingfeng
Mao, Leilei
Zhang, Zongyong
Sun, Baoliang
Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
title Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
title_full Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
title_fullStr Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
title_full_unstemmed Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
title_short Edaravone Dexborneol Treatment Attenuates Neuronal Apoptosis and Improves Neurological Function by Suppressing 4-HNE-Associated Oxidative Stress After Subarachnoid Hemorrhage
title_sort edaravone dexborneol treatment attenuates neuronal apoptosis and improves neurological function by suppressing 4-hne-associated oxidative stress after subarachnoid hemorrhage
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9068884/
https://www.ncbi.nlm.nih.gov/pubmed/35529450
http://dx.doi.org/10.3389/fphar.2022.848529
work_keys_str_mv AT chenqian edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT caiyichen edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT zhuxiaoyu edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT wangjing edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT gaofeng edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT yangmingfeng edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT maoleilei edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT zhangzongyong edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage
AT sunbaoliang edaravonedexborneoltreatmentattenuatesneuronalapoptosisandimprovesneurologicalfunctionbysuppressing4hneassociatedoxidativestressaftersubarachnoidhemorrhage